Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial

Because type 2 diabetes mellitus is associated strongly with an increased risk of cardiovascular diseases, the number of patients with diabetes with chronic heart failure is increasing steadily. However, clini...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Source Type: research

Related Links:

AbstractBackground and AimsDiabetes mellitus (DM) can cause left ventricular (LV) diastolic dysfunction, leading to heart failure with preserved ejection fraction (HFpEF). Dipeptidyl peptidase IV (DPP-IV) inhibitors have failed to reduce hospitalization due to HF in type 2 DM (T2D) patients in a large-scale clinical trial, despite their cardiovascular protective effects. Therefore, it is important to investigate whether DPP-IV inhibitors can improve LV diastolic dysfunction in T2D patients. The aim of the study was to evaluate whether teneligliptin, the strongest of the DPP-IV inhibitors, improves LV dysfunction or prevent...
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
CONCLUSION: The current analysis showed that treatment with DPP-4 inhibitors did not significantly increase cardiovascular outcomes in these patients with T2DM indicating that those drugs might be safe to use in terms of cardiovascular events. PMID: 30832701 [PubMed - in process]
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
AbstractPurpose of ReviewDiabetes mellitus (DM) has become a rising epidemic in the last century, more pressing in the last few decades with the exponential rise of obesity, and has become one of the leading causes of death worldwide.Recent FindingsGenetic variants have also been a new field of epidemiology research to determine the underlying genetic component of those risk factors and the association of DM with CVD.SummaryIn light of its significant prevalence, patients remain unaware of their disease progression that arises from genetic and metabolic risk factors. As compared to non-diabetics, those with type 2 DM carry...
Source: Current Cardiology Reports - Category: Cardiology Source Type: research
Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases worldwide, which leads to myocardial dysfunction and even heart failure in long-term follow-up[1 –3]. The potential pathomechanism of diabetic myocardial damage is multifactorial and result in diffuse myocardial fibrosis [4,5]. Myocardial fibrosis is related to the pathogenesis of left ventricle hypertrophy and has been confirmed in the middle or later stage of diabetic cardialmyopathy, which paly an important role in cardiac structure change and the abnormality of cardiac function[67].
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
Authors: Singh AK, Singh R Abstract INTRODUCTION: Heart failure (HF) in type 2 diabetes mellitus (T2DM) poses a significant increase in mortality. Until recently, anti-diabetic drugs have not been shown to reduce hospitalization due to heart failure (hHF). While thiazolidinedione class and saxagliptin has shown a significantly increased risk, sodium-glucose linked co-transporter 2 inhibitors (SGLT-2Is) have demonstrated a significant reduction in the risk of hHF. Areas covered: We systematically searched the database of PubMed, Embase, ClinicalTrials.gov and International conference presentation up to December 25, ...
Source: Expert Review of Clinical Pharmacology - Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research
We aimed to investigate the association between diabetes duration and the subsequent occurrence of heart failure (HF) in type 2 diabetes mellitus (T2DM) patients without clinical cardiovascular disease. In this single-center, observational cohort study, a total of 3724 T2DM patients were stratified by diabetes duration into three 5-year interval subgroups. The primary outcomes were the occurrence of new-onset HF and all-cause mortality. HF incidence (P 
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Abstract BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose contransporter-2 inhibitors (SGLT2i) have emerged as two new classes of antihyperglycemic agents that also reduce cardiovascular risk. The relative benefits in patients with and without established atherosclerotic cardiovascular disease (ASCVD) for different outcomes with these classes of drugs remain undefined. METHODS: We performed a systematic review and trial-level meta-analysis of GLP1-RA and SGLT2i cardiovascular outcomes trials using the PubMed and EMBASE databases. The primary outcomes were: the composite of my...
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
This study aimed to separately estimate health utility decrements associated with current and previous diabetes complications.Research Design and MethodsThe Health Utilities Index Mark 3 (HUI-3) was used to measure heath utility in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial (N = 8713). Five macrovascular complications (myocardial infarction [MI], congestive heart failure [CHF], stroke, angina, and revascularization surgery [RS]) and three microvascular complications (nephropathy [renal failure], retinopathy [severe vision loss], and neuropathy [severe pressure sensat ion loss]) were ...
Source: PharmacoEconomics - Category: Health Management Source Type: research
This study showed that potential vicious cycles underlying ARDs are quite diverse and unique, triggered by diverse and unique factors that do not usually progress with age, thus casting doubts on the possibility of discovering the single molecular cause of aging and developing the single anti-aging pill. Rather, each disease appears to require an individual approach. However, it still cannot be excluded that some or all of these cycles are triggered by fundamental processes of aging, such as chronic inflammation or accumulation of senescent cells. Nevertheless, experimental data showing clear cause and effect relationships...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
This study investigated the CHA2DS2-VASc score to stratify patients with cardiovascular diseases receiving a fourth-generation synchronous telehealth program. Methods: This was a retrospective cohort study. We recruited patients with cardiovascular disease who received the fourth-generation synchronous telehealth program at the National Taiwan University Hospital between October 2012 and June 2015. We enrolled 431 patients who had joined a telehealth program and compared them to 1549 control patients. Risk of cardiovascular hospitalization was estimated with Kaplan-Meier curves. The CHA2DS2-VASc score was used as the compo...
Source: Journal of Medical Internet Research - Category: General Medicine Authors: Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Heart Failure | Invokana